Beat cancer tomorrow by catching it today.

Advancing early disease and cancer screening using biophysics based Cancer Differentiation Analysis technology.

Ticker Symbol: ANPC (NASDAQ Global Market)

Early cancer screening saves lives and dramatically reduces costs.

Results speak.

26

Cancer types detected

1,000+

Individuals screened out & identified with an early stage of disease

85-90%

Sensitivity & specificity for most cancer types

200,000+

General population screening & clinical research samples

Working together to achieve innovative, patented early disease screening and detection technology tools.

Co-Founder, Dr. Chris Yu and Dr. Herbert Yu have assembled an integrated research and development team from both China and United States. Our research and development team has a multi-disciplinary background, and most members of this team specialize in areas related or helpful to the development of our CDA technology and device, including mechatronics, physics, biomedical science or computer science. 

“game changing”

Read about our CDA technology at the Nobel Prize Laureate Summit on Biomedical Science (NPLS) publications.

Read the full article

Our Medical & Research Partners

Anpac Bio has partnered with hospitals and medical institutions to conduct several studies in the U.S and China. Read the research Anpac Bio scientists presented at the American Society of Clinical Oncology (ASCO), the San Antonio Breast Cancer Symposium, and the Nobel Prize Laureate Summit on Biomedical Sciences.

Read the Abstracts

©2019 Anpac Bio-Medical Science Co., Ltd.